NYSE · Biotechnology · USD
Annovis Bio, Inc. (ANVS) Stock Analysis
Annovis Bio, Inc. (ANVS) is a Biotechnology stock listed on NYSE and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ANVS Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.00
- Previous Close
- $0.98
- Day's Range
- 0.99–1.04
- 52-Week Range
- 0.95–5.50
- Volume
- 546.33K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.23
Valuation
- Market Cap
- $42.39M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.75
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$28.85M
- Shares Outstanding
- 42.68M
- 1-Year Return
- −54.23%
Dividend and dates
- Avg Volume
- 868.55K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ANVS closed at $0.99, −54.23% over 1 year.
Annovis Bio, Inc. (ANVS) has a market capitalization of $42.39M.
In fiscal 2025, ANVS reported revenue of $0.00.
ANVS Stock Return by Calendar Year
Annovis Bio, Inc. (ANVS) return since Jan 2020: what $10,000 became
- 1 year
- $10,000 $4,577
- −54.23%
- 5 years
- $10,000 $338
- −96.62%
- Since Jan 2020
- $10,000 $1,036
- −89.64%
If you had invested $10,000 in Annovis Bio, Inc. (ANVS) at the close on January 29, 2020, the earliest close on record here, it would have been worth $1,036 at the close on October 21, 2026: −89.64% in total, −28.62% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −71.29% |
| 2025 | −31.21% |
| 2024 | −73.10% |
| 2023 | +39.24% |
| 2022 | −23.61% |
| 2021 | +133.16% |
| 2020 | −21.38% |
As of October 21, 2026.
ANVS Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$28.85M | — |
| 2024 | $0.00 | −$24.59M | — |
| 2023 | $0.00 | −$56.20M | — |
| 2022 | $0.00 | −$25.33M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$29.70M | −$28.85M | — |
| 2024 | $0.00 | — | −$26.69M | −$24.59M | — |
| 2023 | $0.00 | — | −$45.04M | −$56.20M | — |
| 2022 | $0.00 | — | −$25.51M | −$25.33M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
YahooAnnovis Bio Consensus Price Target Lowered by 16.67% to $10.71
FintelAnnovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
YahooAnnovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
MarketBeatRoth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7
BenzingaAnnovis Bio Q2 EPS $(0.40) Beats $(0.45) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B